Clinical evidence for second- and third-line treatment options in advanced non-small cell lung cancer

Research output: Contribution to journalArticle

53 Citations (Scopus)

Abstract

In the U.S. and Europe, the current options for the second- and third-line treatment of advanced non-small cell lung cancer (NSCLC) are cytotoxic drugs and targeted agents. Docetaxel was the first drug approved for second-line treatment after two phase III trials demonstrated its superiority over best supportive care (BSC) alone and single-agent chemotherapy. Pemetrexed was also registered for use as second-line therapy after it was demonstrated to have activity comparable with, and a more favorable toxicity profile than, docetaxel. Erlotinib, an epidermal growth factor receptor inhibitor, is the only biological agent to have been approved in the U.S. and Europe for lung cancer treatment after a study showed its superiority over BSC in recurrent (second-/third-line) NSCLC patients. This review focuses on these drugs, dealing with the results supporting the choice among docetaxel, pemetrexed, and erlotinib in second- and/or third-line treatment.

Original languageEnglish
Pages (from-to)14-20
Number of pages7
JournalThe oncologist
Volume13
Issue numberSUPPL. 1
DOIs
Publication statusPublished - 2008

Fingerprint

docetaxel
Non-Small Cell Lung Carcinoma
Pemetrexed
Pharmaceutical Preparations
Therapeutics
Biological Factors
Epidermal Growth Factor Receptor
Lung Neoplasms
Drug Therapy

Keywords

  • Docetaxel
  • Erlotinib
  • NSCLC
  • Pemetrexed
  • Second-line chemotherapy

ASJC Scopus subject areas

  • Cancer Research
  • Oncology
  • Hematology

Cite this

@article{7b264a6792a143ac84edadb17eb79647,
title = "Clinical evidence for second- and third-line treatment options in advanced non-small cell lung cancer",
abstract = "In the U.S. and Europe, the current options for the second- and third-line treatment of advanced non-small cell lung cancer (NSCLC) are cytotoxic drugs and targeted agents. Docetaxel was the first drug approved for second-line treatment after two phase III trials demonstrated its superiority over best supportive care (BSC) alone and single-agent chemotherapy. Pemetrexed was also registered for use as second-line therapy after it was demonstrated to have activity comparable with, and a more favorable toxicity profile than, docetaxel. Erlotinib, an epidermal growth factor receptor inhibitor, is the only biological agent to have been approved in the U.S. and Europe for lung cancer treatment after a study showed its superiority over BSC in recurrent (second-/third-line) NSCLC patients. This review focuses on these drugs, dealing with the results supporting the choice among docetaxel, pemetrexed, and erlotinib in second- and/or third-line treatment.",
keywords = "Docetaxel, Erlotinib, NSCLC, Pemetrexed, Second-line chemotherapy",
author = "Marinis, {Filippo De} and Francesco Grossi",
year = "2008",
doi = "10.1634/theoncologist.13-S1-14",
language = "English",
volume = "13",
pages = "14--20",
journal = "Oncologist",
issn = "1083-7159",
publisher = "Wiley Blackwell",
number = "SUPPL. 1",

}

TY - JOUR

T1 - Clinical evidence for second- and third-line treatment options in advanced non-small cell lung cancer

AU - Marinis, Filippo De

AU - Grossi, Francesco

PY - 2008

Y1 - 2008

N2 - In the U.S. and Europe, the current options for the second- and third-line treatment of advanced non-small cell lung cancer (NSCLC) are cytotoxic drugs and targeted agents. Docetaxel was the first drug approved for second-line treatment after two phase III trials demonstrated its superiority over best supportive care (BSC) alone and single-agent chemotherapy. Pemetrexed was also registered for use as second-line therapy after it was demonstrated to have activity comparable with, and a more favorable toxicity profile than, docetaxel. Erlotinib, an epidermal growth factor receptor inhibitor, is the only biological agent to have been approved in the U.S. and Europe for lung cancer treatment after a study showed its superiority over BSC in recurrent (second-/third-line) NSCLC patients. This review focuses on these drugs, dealing with the results supporting the choice among docetaxel, pemetrexed, and erlotinib in second- and/or third-line treatment.

AB - In the U.S. and Europe, the current options for the second- and third-line treatment of advanced non-small cell lung cancer (NSCLC) are cytotoxic drugs and targeted agents. Docetaxel was the first drug approved for second-line treatment after two phase III trials demonstrated its superiority over best supportive care (BSC) alone and single-agent chemotherapy. Pemetrexed was also registered for use as second-line therapy after it was demonstrated to have activity comparable with, and a more favorable toxicity profile than, docetaxel. Erlotinib, an epidermal growth factor receptor inhibitor, is the only biological agent to have been approved in the U.S. and Europe for lung cancer treatment after a study showed its superiority over BSC in recurrent (second-/third-line) NSCLC patients. This review focuses on these drugs, dealing with the results supporting the choice among docetaxel, pemetrexed, and erlotinib in second- and/or third-line treatment.

KW - Docetaxel

KW - Erlotinib

KW - NSCLC

KW - Pemetrexed

KW - Second-line chemotherapy

UR - http://www.scopus.com/inward/record.url?scp=42049089207&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=42049089207&partnerID=8YFLogxK

U2 - 10.1634/theoncologist.13-S1-14

DO - 10.1634/theoncologist.13-S1-14

M3 - Article

C2 - 18263770

AN - SCOPUS:42049089207

VL - 13

SP - 14

EP - 20

JO - Oncologist

JF - Oncologist

SN - 1083-7159

IS - SUPPL. 1

ER -